PDCD1 and hepatocellular carcinoma: As a leading therapeutic in immunotherapy targeting programmed cell death 1 protein (PD-1), nivolumab demonstrated a 20% objective response rate and a 64% disease control rate in HCC patients who progressed on sorafenib [16].